SynKIR-110 is intended for the treatment of mesothelin-expressing solid tumours. Credit: Kateryna Kon / Shutterstock.

Verismo Therapeutics has dosed the first patient in the first-in-human Phase I STAR-101 clinical trial of SynKIR-110 to treat advanced cancers.

The dose-escalation, open-label, multicentre study is designed to assess the feasibility, safety, and potential activity of SynKIR-110 in patients with mesothelin-expressing solid tumours including advanced ovarian cancer, pleural mesothelioma, and cholangiocarcinoma.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Up to 42 participants aged 18 years and above will receive a single intravenous dose of SynKIR-110. They will be divided into up to six cohorts of three to six subjects in each cohort.

Doses will be escalated in a standard 3+3 pattern until a maximum tolerated dose (MTD), or a maximum feasible dose (MFD) is reached.

To further assess the safety and potential activity of SynKIR-110, an additional six to nine subjects will be enrolled at the MTD/MFD.

The study also includes an intervention period where subjects will receive non-myeloablative lymphodepleting chemotherapy followed by a single infusion of SynKIR-110.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Subjects will be followed for 12 months or until disease progression.

The SynKIR-110 product comprises autologous T cells transduced with a mesothelin-targeted KIR-CAR platform.

This platform is a dual-chain CAR T cell therapy that is capable of maintaining antitumour T cell activity in challenging solid tumour environments.

Last June, Verismo and the University of Pennsylvania (Penn) entered a sponsored research agreement to expedite new treatment options for solid tumour indications.

Verismo Therapeutics co-founder and CEO Dr Bryan Kim said: “This represents a significant milestone for our company and demonstrates the commitment of our team to address the critical need for additional treatment options for patients with mesothelin-expressing solid tumours.

“We’re proud to work with the distinguished team at Penn to take our SynKIR-110 treatment out of the lab and to the patients with unmet medical needs.”

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.